✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
Aligos Therapeutics, Inc.
operating
Overview
Aligos Therapeutics, Inc. is a operating registered in SOUTH SAN FRANCISCO, United States. With reported revenue of 2.2M USD in 2025. Its TraceComp score of 53 (C) indicates elevated risk requiring further due diligence.
Company Information
- Registration Number
- 0001799448
- Legal Form
- operating
- Activity
- Biological Products, (No Diagnostic Substances)
- Address
- south-san-francisco
Financial Profile
Latest filed accounts: FY 2025
Multi-year financials & ratios
1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
No officers on record.
Patent Portfolio
Active patent holder. 33 patents · 33 active · 33 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Net loss reported in FY 2025
Similar Companies
Data Sources & Freshness
Data sourced from: official public registries. Profile completeness: 70%.